Type of Assessment:
From biology to therapy: current standards and emerging strategies in pleural mesothelioma
Frontiers in Oncology 2026 March 26 [Link] J H L T van Genugten, C J de Gooijer, Paul Baas Abstract Pleural mesothelioma (PM) is an aggressive malignancy with limited therapeutic options and poor long-term prognosis. Platinum-based chemotherapy has been the standard-of-care for most patients for decades. While the decoding of the genomic alterations in PM…
Read MoreGene expression and immunohistochemical phenotypes of high-grade epithelioid mesothelioma
Human Pathology 2026 July [Link] Marie-France Gagnon, Krasimira Rozenova, Chien Lu, Carlos Sosa, Beth Pitel, Matthew Petersen, Sydney Clausen, Anja C Roden, Kevin C Halling, Ying-Chun Lo Abstract Grading of epithelioid mesothelioma (EM) has recently been reported to be predictive of survival. We investigated whether RNA expression profiles and immunohistochemical (IHC) markers could refine EG…
Read MoreUpdate on pleural epithelioid mesothelioma: New insights for diagnosis and patient management
Journal of Thoracic Oncology 2026 April 8 [Link] Francoise Galateau Sallé, Mary Beth Beasley, Luka Brcic, Wendy Cooper 4, Sanja Dacic, Marc de Perrot, Ming-Sound Tsao, Sonja Klebe, Andrew Churg, Aaron S Mansfield, Paul Baas Abstract Diffuse Mesothelioma is typically diagnosed through histopathologic evaluation. Recent advances in therapeutic strategies have heightened the importance of accurate…
Read MorePseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics
Cell Death & Disease 2026 April 10 [Link] Iswarya Sreeram, Sílvia Plans-Marin, Mabel Cruz-Rodríguez, Elisabet Aliagas, Didac Palau-Gallinat, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Pleural Mesothelioma (PM) is an aggressive neoplasm of the lung pleura with poor survival rates, highlighting the urgent need for novel therapeutic options. The CDK4/6 inhibitors abemaciclib and palbociclib have demonstrated promising…
Read MoreA case of delayed recurrence of pleural mesothelioma with intradural invasion
Surgical Neurology International 2026 March 20 [Link] Hidetoshi Sato, Rui Omichi, Yuto Nigami, Nobuyuki Shimokawa Abstract Background: Pleural mesothelioma (PM) is a tumor of the pleural epithelium with a poor prognosis. Asbestos exposure is closely related to its occurrence. To date, there have been 13 reports of PM with intradural invasion. Case description: A 73-year-old male was…
Read MoreBrain Metastases in Diffuse Pleural Mesothelioma: Clinical, Histologic, and Molecular Correlates
JTO Clinical and Research Reports 2026 February 5 [Link] Antonio Ocejo, Clare Wilhem, Francis M Bodd, Andrea Arfe, Marjorie G Zauderer, Afsheen Iqbal, Juliana Eng, Yao Yu, Joshua A Budhu, Javin Schefflein, Robert Young, Mark G Kris, Nelson S Moss, Rabih Bou-Nassif, Charles B Simone 2nd, Prasad S Adusumilli, Jennifer L Sauter, Michael Offin Abstract…
Read MoreThe Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas
International Journal of Surgical Pathology 2026 April 6 [Link] Hale Kivrak, İlke Evrim Secinti, Egemen Akincioglu, Elcin Kadan, Ertugrul Celik, Gulcin Guler Simsek Abstract Objectives: Mesothelioma is an aggressive cancer that is often not suitable for curative surgery. It can be difficult to distinguish from reactive processes and other malignancies, especially in small biopsies, and outcomes of systemic therapies remain…
Read MoreClinical, diagnostic and prognostic relevance of GATA3 in malignant pleural mesothelioma: a retrospective cohort study
BMC Cancer 2026 April 2 [Link] Alejandro Avilés-Salas, David Dávila Dupont, Alejandro Aranda-Gutierrez, Andrea Nallely Heredia-Jara, Enrique Caballé-Perez, Luis Cabrera-Miranda, Andrés F Cardona, José Lucio-Lozada, Cesar Castillo-Ruiz, Norma Hernandez-Pedro, Luis Corrales, Claudio Martin, Oscar Arrieta Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a poor prognosis and limited treatment options. Recently, GATA3 has emerged as a useful adjunct immunohistochemical marker, especially for non-epithelioid subtypes. Although…
Read MoreRadioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin
Pharmaceuticals 2026 March 18 [Link] Hirofumi Hanaoka, Aiko Yamaguchi, Masahiro Maeda, Tatsuya Segawa, Noboru Oriuchi Abstract Background/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods:…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read More
Skip to content